Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections

Lauren C. Russell; Jeff Klaus; Miguel A. Chavez; Erik R. Dubberke; Tamara Krekel

doi:10.1017/ash.2025.179

Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections

Lauren C. Russell
, Jeff Klaus
, Miguel A. Chavez
, Erik R. Dubberke
, Tamara Krekel

Research output: Contribution to journal › Article › peer-review

Abstract

The safety of the utilization of methicillin-susceptible Staphylococcus aureus (MSSA)-Targeted therapy for the treatment of MSSA bloodstream infections in the setting of neutropenia is not well studied. This single-center, retrospective cohort study of 40 patients found no significant difference in clinical outcomes between broad-spectrum anti-Pseudomonal and MSSA-Targeted beta-lactam therapy.

Original language	English
Article number	e108
Journal	Antimicrobial Stewardship and Healthcare Epidemiology
Volume	5
Issue number	1
DOIs	https://doi.org/10.1017/ash.2025.179
State	Published - May 13 2025

Access to Document

10.1017/ash.2025.179

Cite this

Russell, L. C., Klaus, J., Chavez, M. A., Dubberke, E. R., & Krekel, T. (2025). Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrobial Stewardship and Healthcare Epidemiology, 5(1), Article e108. https://doi.org/10.1017/ash.2025.179

@article{9d7e6357546242d696c14440e4fb6cf0,

title = "Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections",

abstract = "The safety of the utilization of methicillin-susceptible Staphylococcus aureus (MSSA)-Targeted therapy for the treatment of MSSA bloodstream infections in the setting of neutropenia is not well studied. This single-center, retrospective cohort study of 40 patients found no significant difference in clinical outcomes between broad-spectrum anti-Pseudomonal and MSSA-Targeted beta-lactam therapy.",

author = "Russell, \{Lauren C.\} and Jeff Klaus and Chavez, \{Miguel A.\} and Dubberke, \{Erik R.\} and Tamara Krekel",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2025.",

year = "2025",

month = may,

day = "13",

doi = "10.1017/ash.2025.179",

language = "English",

volume = "5",

journal = "Antimicrobial Stewardship and Healthcare Epidemiology",

issn = "2732-494X",

number = "1",

}

Russell, LC, Klaus, J, Chavez, MA , Dubberke, ER & Krekel, T 2025, 'Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections', Antimicrobial Stewardship and Healthcare Epidemiology, vol. 5, no. 1, e108. https://doi.org/10.1017/ash.2025.179

Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections. / Russell, Lauren C.; Klaus, Jeff; Chavez, Miguel A. et al.
In: Antimicrobial Stewardship and Healthcare Epidemiology, Vol. 5, No. 1, e108, 13.05.2025.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections

AU - Russell, Lauren C.

AU - Klaus, Jeff

AU - Chavez, Miguel A.

AU - Dubberke, Erik R.

AU - Krekel, Tamara

PY - 2025/5/13

Y1 - 2025/5/13

N2 - The safety of the utilization of methicillin-susceptible Staphylococcus aureus (MSSA)-Targeted therapy for the treatment of MSSA bloodstream infections in the setting of neutropenia is not well studied. This single-center, retrospective cohort study of 40 patients found no significant difference in clinical outcomes between broad-spectrum anti-Pseudomonal and MSSA-Targeted beta-lactam therapy.

AB - The safety of the utilization of methicillin-susceptible Staphylococcus aureus (MSSA)-Targeted therapy for the treatment of MSSA bloodstream infections in the setting of neutropenia is not well studied. This single-center, retrospective cohort study of 40 patients found no significant difference in clinical outcomes between broad-spectrum anti-Pseudomonal and MSSA-Targeted beta-lactam therapy.

UR - https://www.scopus.com/pages/publications/105005147600

U2 - 10.1017/ash.2025.179

DO - 10.1017/ash.2025.179

M3 - Article

C2 - 40391165

AN - SCOPUS:105005147600

SN - 2732-494X

VL - 5

JO - Antimicrobial Stewardship and Healthcare Epidemiology

JF - Antimicrobial Stewardship and Healthcare Epidemiology

IS - 1

M1 - e108

ER -

Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections

Abstract

Access to Document

Other files and links

Fingerprint

Cite this